| Revenue | DKK -24K | +60% |
| EBITDA | DKK -24K | -60% |
| Net profit | DKK -103K | +89% |
| Total assets | DKK 0 | -100% |
| Equity | DKK -7,3M | -1% |
| Employees | — | — |
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|---|
| Revenue | -22 | -18 | -18 | -14 | -15 | -15 | -24 |
| Staff expenses | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBITDA | -22 | -18 | -18 | -14 | -15 | -15 | -24 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBIT | -22 | -18 | -18 | -14 | -15 | -15 | -24 |
| Net financials | -406 | -65 | -4.922 | -671 | -392 | -918 | -79 |
| Profit before tax | -428 | -83 | -4.940 | -685 | -407 | -933 | -103 |
| Tax | -0 | -141 | -0 | -0 | -0 | -0 | -0 |
| Net profit | -428 | 58 | -4.940 | -685 | -407 | -933 | -103 |
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|---|
| Total assets | 4.799 | 5.369 | 988 | 681 | 673 | 159 | 0 |
| Equity | -303 | -245 | -5.186 | -5.871 | -6.278 | -7.211 | -7.313 |
| Long-term debt | 3.620 | 4.607 | 4.607 | 4.607 | 0 | 0 | 0 |
| Short-term debt | 1.482 | 1.007 | 1.567 | 1.945 | 6.951 | 7.369 | 7.313 |
| Total debt | 5.102 | 5.614 | 6.174 | 6.552 | 6.951 | 7.369 | 7.313 |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
PL Management | Management | 2015 | — | — |
JE Management | Management | 2015 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Chairman | 2015 | — | — | |
| Board of Directors | 2015 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
New Beginning Aps | Company | 66.7% | 66.7% | 2023 |
PHARMAVIE A/S | Company | 20.0% | 20.0% | 2023 |
MRH VEJLE ApS | Company | 66.7% | 66.7% | 2015 |
| Person | Role here | Other companies |
|---|---|---|
| Peter Larsen | Management | 0 companies |
| Jacob Ejs | Management | 0 companies |
| Carsten Wærn | Chairman | 0 companies |
| Leif Dambo Jensen | Board of Directors | 0 companies |